within Pharmacolibrary.Drugs.ATC.J;

model J01MA19
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 8.833333333333333e-05,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0613,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0492,
    k12             = 24.4,
    k21             = 24.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01MA19</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Garenoxacin is an oral des-fluoroquinolone antibiotic formerly used to treat bacterial infections, particularly respiratory and urinary tract infections. It demonstrates activity against a broad spectrum of Gram-positive and Gram-negative bacteria. Garenoxacin was approved for use in some countries (e.g., Japan), but is not currently approved in the United States or the European Union.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Gajjar, DA, et al., &amp; Grasela, DM (2003). Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. <i>Antimicrobial agents and chemotherapy</i> 47(7) 2256–2263. DOI:<a href=&quot;https://doi.org/10.1128/AAC.47.7.2256-2263.2003&quot;>10.1128/AAC.47.7.2256-2263.2003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12821477/&quot;>https://pubmed.ncbi.nlm.nih.gov/12821477</a></p></li><li><p>Krishna, G, et al., &amp; Wang, Z (2007). Garenoxacin pharmacokinetics in subjects with renal impairment. <i>Current medical research and opinion</i> 23(3) 649–657. DOI:<a href=&quot;https://doi.org/10.1185/030079906X167679&quot;>10.1185/030079906X167679</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17355746/&quot;>https://pubmed.ncbi.nlm.nih.gov/17355746</a></p></li><li><p>Takagi, H, et al., &amp; Kobayashi, H (2008). Clinical studies of garenoxacin. <i>International journal of antimicrobial agents</i> 32(6) 468–474. DOI:<a href=&quot;https://doi.org/10.1016/j.ijantimicag.2008.06.032&quot;>10.1016/j.ijantimicag.2008.06.032</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18790608/&quot;>https://pubmed.ncbi.nlm.nih.gov/18790608</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01MA19;
